ADIAL PHARMACEUTICALS, INC. short interest in 2024
In 2024, ADIAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 3.05% of shares outstanding on 12 Jan 2024 to 2.73% on 15 Nov 2024, a change of -0.32 percentage points. The year's high was 24.90% on 15 Apr 2024 and its low 0.80% on 15 Oct 2024, averaging 4.48% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.98 days on 15 Jul 2024. Full history: ADIAL PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 3.05% (12 Jan 2024)
- End of year
- 2.73% (15 Nov 2024)
- Change
- -0.32 pp
- High
- 24.90% (15 Apr 2024)
- Low
- 0.80% (15 Oct 2024)
- Average
- 4.48%
- Highest days to cover
- 2.98 (15 Jul 2024)
- SEC filings marked
- 4
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 3.05% | 1.00 | |
| 31 Jan 2024 | 1.80% | 1.25 | |
| 29 Feb 2024 | 2.31% | 1.00 | |
| 15 Apr 2024 | 24.90% | 1.00 | 10-K filed |
| 15 May 2024 | 3.13% | 1.00 | 10-Q filed |
| 31 May 2024 | 3.86% | 1.28 | |
| 14 Jun 2024 | 5.15% | 1.00 | |
| 28 Jun 2024 | 3.86% | 1.55 | |
| 15 Jul 2024 | 3.61% | 2.98 | |
| 31 Jul 2024 | 6.95% | 1.00 | |
| 15 Aug 2024 | 4.98% | 1.53 | 10-Q filed |
| 30 Aug 2024 | 4.26% | 1.85 | |
| 13 Sep 2024 | 2.29% | 1.16 | |
| 30 Sep 2024 | 1.22% | 1.00 | |
| 15 Oct 2024 | 0.80% | 1.00 | |
| 31 Oct 2024 | 1.23% | 1.00 | |
| 15 Nov 2024 | 2.73% | 1.00 | 10-Q filed |
See also: ADIAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.